Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00488137
Recruitment Status : Completed
First Posted : June 19, 2007
Last Update Posted : September 26, 2013
Information provided by:

Brief Summary:

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic constipation.


Prucalopride 2 mg and 4 mg given once daily for 12 weeks is superior to placebo for the treatment of patients with chronic constipation and is well tolerated in those patients

Condition or disease Intervention/treatment Phase
Constipation Drug: Prucalopride Other: Placebo Phase 3

Detailed Description:

This is a multicentre, Phase III trial with a parallel-group design, consisting of a 2 week drug-free run-in period, followed by a 12-week, double-blind, placebo-controlled treatment period.

During the run-in period, the subject's bowel habit will be documented and the existence of constipation confirmed. At the start of this period, all existing laxative medication will be withdrawn and subjects will be instructed not to change their diet or lifestyle during the trial. Subjects will be allowed to take a laxative (Dulcolax) as a rescue medication throughout the trial, but only if they have not had a bowel movement for three or more consecutive days. No Dulcolax should be taken or enemas used within 48 hours prior to the start of the double-blind treatment (48 hours prior to visit 2) and 48 hours following the start of double-blind treatment (48 hours following visit 2). Subjects will enter the double-blind period if constipation is shown to be present during the run-in period.

If the definition of constipation is not met during the 2-week run-in, the subject will be considered ineligible for the double-blind period and will be discontinued from the study.

During the double-blind, randomised, placebo-controlled period, subjects will be treated for 12 weeks with either 2 mg or 4 mg R108512 or placebo, given once daily before breakfast.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 716 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation
Study Start Date : March 1998
Actual Primary Completion Date : July 1999
Actual Study Completion Date : July 1999

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Prucalopride 2 mg
Drug: Prucalopride
2 mg o.d.
Other Name: Resolor
Placebo Comparator: 3
Other: Placebo
Active Comparator: 2
Prucalopride 4 mg
Drug: Prucalopride
4 mg o.d.
Other Name: Resolor

Primary Outcome Measures :
  1. Proportion of subjects with an average of 3 or more SCBM per week [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Secondary efficacy variables: 1) Symptom variables 2) QOL variables [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age (no upper age limit).
  2. History of constipation; the subject reports, on average, two or fewer spontaneous bowel movements per week that result in a feeling of complete evacuation and one or more of the following for at least 6 months before the selection visit:

    1. very hard (little balls) and/or hard stools at least a quarter of the stools
    2. sensation of incomplete evacuation following at least a quarter of the stools
    3. straining at defecation at least a quarter of the time. The above criteria are only applicable for spontaneous bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.

Subjects who never have spontaneous bowel movements are considered to be constipated and are eligible for the trial.

Exclusion Criteria:

  1. Subjects in whom constipation is thought to be drug-induced, or subjects using any disallowed medication.
  2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic disorders.
  3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.
  4. Constipation as a result of surgery.
  5. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma, or inflammatory bowel disease.
  6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer or AIDS, and other gastrointestinal or endocrine disorders.
  7. Subjects with impaired renal function.
  8. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.
  9. Females of child-bearing potential without adequate contraceptive protection during the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00488137

Sponsors and Collaborators
Principal Investigator: Ghislain Devroede, M.D. Centre Universitaire de Sante

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Renate Specht Gryp, Movetis Identifier: NCT00488137     History of Changes
Other Study ID Numbers: PRU-INT-6
First Posted: June 19, 2007    Key Record Dates
Last Update Posted: September 26, 2013
Last Verified: September 2013

Keywords provided by Movetis:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms